{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:46:51Z","timestamp":1787010411499,"version":"build-2736575974"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Cancer therapies often result in the \u2018late effect of cancer treatment\u2019 whereby secondary health complications emerge years after radiotherapy and chemotherapy. This review focuses on endocrine and metabolic consequences in adult cancer survivors as late treatment effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Endocrine and metabolic disorders are among the most common late effects. Endocrine disorders include hypopituitarism, which leads to growth hormone deficiency, hypogonadism, adrenal insufficiency and hypothyroidism and related clinical manifestations. Hypogonadism in particular is associated with a wide range of health complications requiring input from the like of endocrine and fertility specialists. Immune checkpoint inhibitors are novel anticancer agents, some of which are uniquely associated with hypophysitis which requires early recognition and management, including steroid replacement. Metabolic syndrome, a significant risk for cardiovascular disease, is highly prevalent. Although the effects of cranial irradiation on the hypothalamic\u2013pituitary system are more apparent, the relationship between chemotherapy and endocrine\/metabolic disorders remains to be elucidated. There exist published guidelines for monitoring endocrine and cardiometabolic risk in cancer survivors, but the extent of monitoring appears insufficient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Regular monitoring and early management of endocrine\/metabolic disorders is required to prevent the elevated rates of health complications after cancer treatment, and thereby improve cancer survivorship.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/spc.0000000000000289","type":"journal-article","created":{"date-parts":[[2017,6,28]],"date-time":"2017-06-28T10:48:04Z","timestamp":1498646884000},"page":"205-213","source":"Crossref","is-referenced-by-count":12,"title":["Long-term and late treatment consequences: endocrine and metabolic effects"],"prefix":"10.1097","volume":"11","author":[{"given":"Thang S.","family":"Han","sequence":"first","affiliation":[{"name":"Institute of Cardiovascular Research, Royal Holloway, University of London & Ashford and St Peter's Hospitals NHS Foundation Trust, Egham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena K.","family":"Gleeson","sequence":"additional","affiliation":[{"name":"University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230926","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.bjc.6605148","article-title":"Cancer prevalence in the United Kingdom: estimates for 2008","volume":"101","author":"Maddams","year":"2009","journal-title":"Br J Cancer"},{"key":"R2-20230926","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/bjc.2012.366","article-title":"Projections of cancer prevalence in the United Kingdom, 2010\u20132040","volume":"107","author":"Maddams","year":"2012","journal-title":"Br J Cancer"},{"key":"R3-20230926","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0140-6736(14)61396-9","article-title":"40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971\u20132011: a population-based study","volume":"385","author":"Quaresma","year":"2015","journal-title":"Lancet"},{"key":"R4-20230926","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S1470-2045(05)70251-5","article-title":"Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries","volume":"6","author":"Darby","year":"2005","journal-title":"Lancet Oncol"},{"key":"R5-20230926","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2010.29.9362","article-title":"Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study","volume":"28","author":"Haugnes","year":"2010","journal-title":"J Clin Oncol"},{"key":"R6-20230926","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1210\/jc.2011-0306","article-title":"Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis","volume":"96","author":"Appelman-Dijkstra","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20230926","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2213-8587(15)00008-X","article-title":"Effect of cancer treatment on hypothalamic\u2013pituitary function","volume":"3","author":"Crowne","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R8-20230926","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0140-6736(00)02717-3","article-title":"Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood","volume":"356","author":"Taskinen","year":"2000","journal-title":"Lancet"},{"key":"R9-20230926","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.12754","article-title":"Metabolic syndrome and cardiovascular risk among long-term survivors of acute lymphoblastic leukaemia \u2013 from the St. Jude Lifetime Cohort","volume":"165","author":"Nottage","year":"2014","journal-title":"Br J Haematol"},{"key":"R10-20230926","first-page":"S89","article-title":"Metabolic syndrome is common following haematopoietic cell transplantation (HCT) and is associated with increased cardiovascular disease: an EBMT cross-sectional noninterventional study","volume":"50","author":"Greenfield","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R11-20230926","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/jnci\/djn310","article-title":"Cause-specific late mortality among 5-year survivors of childhood cancer: The Childhood Cancer Survivor Study","volume":"100","author":"Mertens","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R12-20230926","article-title":"How well are patients with myeloproliferative neoplasms assessed for cardiovascular risk: an audit report","volume":"7","author":"Sekhar","year":"2015","journal-title":"Online J Clin Audits"},{"key":"R13-20230926","doi-asserted-by":"crossref","DOI":"10.7861\/clinmedicine.17-4-293","article-title":"Monitoring cardiovascular disease risk factors in cancer survivors","author":"Kapoor","year":"2017","journal-title":"Clin Med"},{"key":"R14-20230926","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1677\/joe.0.1500329","article-title":"Evolution of growth hormone neurosecretory disturbance after cranial irradiation for childhood brain tumours: a prospective study","volume":"150","author":"Spoudeas","year":"1996","journal-title":"J Endocrinol"},{"key":"R15-20230926","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3476(05)80487-1","article-title":"Dose dependency of time of onset of radiation-induced growth hormone deficiency","volume":"118","author":"Clayton","year":"1991","journal-title":"J Pediatr"},{"key":"R16-20230926","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1365-2265.2000.01079.x","article-title":"Cranial radiotherapy of childhood brain tumours: growth hormone deficiency and its relation to the biological effective dose of irradiation in a large population based study","volume":"53","author":"Schmiegelow","year":"2000","journal-title":"Clin Endocrinol"},{"key":"R17-20230926","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1210\/jc.2004-2002","article-title":"The dynamics of growth hormone (GH) secretion in adult cancer survivors with severe GH deficiency acquired after brain irradiation in childhood for nonpituitary brain tumors: evidence for preserved pulsatility and diurnal variation with increased secretory disorderliness","volume":"90","author":"Darzy","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"R18-20230926","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJM199301143280203","article-title":"Hypothalamic\u2013pituitary dysfunction after radiation for brain tumors","volume":"328","author":"Constine","year":"1993","journal-title":"N Engl J Med"},{"key":"R19-20230926","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/sj.bmt.1701769","article-title":"Nutritional status and growth after bone marrow transplantation (BMT) during childhood: EBMT Late-Effects Working Party retrospective data","volume":"23","author":"Cohen","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"(Suppl 1)","key":"R20-20230926","first-page":"86","article-title":"Growth and growth hormone status after a bone marrow transplant","volume":"58","author":"Shalet","year":"2002","journal-title":"Horm Res"},{"issue":"(Suppl 2)","key":"R21-20230926","first-page":"109","article-title":"Effect of radiation on the human reproductive system","volume":"101","author":"Ogilvy-Stuart","year":"1993","journal-title":"Environ Health Perspect"},{"key":"R22-20230926","first-page":"2446","article-title":"Gonadal status in male survivors following childhood brain tumors","volume":"86","author":"Schmiegelow","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"R23-20230926","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1210\/jc.2002-020380","article-title":"A population-based study of thyroid function after radiotherapy and chemotherapy for a childhood brain tumor","volume":"88","author":"Schmiegelow","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R24-20230926","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1093\/humrep\/16.9.1838","article-title":"Hypothalamic\u2013pituitary\u2013ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia","volume":"16","author":"Bath","year":"2001","journal-title":"Hum Reprod"},{"key":"R25-20230926","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/adc.67.9.1107","article-title":"Endocrine deficit after fractionated total body irradiation","volume":"67","author":"Ogilvy-Stuart","year":"1992","journal-title":"Arch Dis Child"},{"key":"R26-20230926","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/pbc.22082","article-title":"Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study","volume":"53","author":"Chow","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"R27-20230926","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1365-2265.1992.tb02903.x","article-title":"A novel variant of growth hormone (GH) insufficiency following low dose cranial irradiation","volume":"36","author":"Crowne","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R28-20230926","first-page":"1282","article-title":"Cranial irradiation and early puberty","volume":"78","author":"Ogilvy-Stuart","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-20230926","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/adc.62.11.1107","article-title":"Precocious and premature puberty associated with treatment of acute lymphoblastic leukaemia","volume":"62","author":"Leiper","year":"1987","journal-title":"Arch Dis Child"},{"key":"R30-20230926","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S2213-8587(15)00039-X","article-title":"Cancer treatment and gonadal function: experimental and established strategies for fertility preservation in children and young adults","volume":"3","author":"Anderson","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R31-20230926","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0360-3016(97)00117-X","article-title":"Hypothyroidism after external radiotherapy for head and neck cancer","volume":"39","author":"Tell","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R32-20230926","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/neuonc\/nov302","article-title":"Endocrine outcomes with proton and photon radiotherapy for standard risk medulloblastoma","volume":"18","author":"Eaton","year":"2016","journal-title":"Neuro Oncol"},{"key":"R33-20230926","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.ijrobp.2014.04.053","article-title":"Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas","volume":"89","author":"Greenberger","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R34-20230926","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1515\/JPEM.2004.17.1.55","article-title":"Hypothalamic dysfunction after chemotherapy","volume":"17","author":"Rose","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R35-20230926","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/1097-0142(19921001)70:7<2013::AID-CNCR2820700734>3.0.CO;2-J","article-title":"The effects of adjuvant chemotherapy on growth in children with medulloblastoma","volume":"70","author":"Olshan","year":"1992","journal-title":"Cancer"},{"key":"R36-20230926","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1651-2227.1995.tb13864.x","article-title":"Effect of chemotherapy on growth","volume":"411","author":"Ogilvy-Stuart","year":"1995","journal-title":"Acta Paediatr Suppl"},{"key":"R37-20230926","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1210\/jc.2003-031224","article-title":"Reassessment of growth hormone status is required at final height in children treated with growth hormone replacement after radiation therapy","volume":"89","author":"Gleeson","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R38-20230926","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/471561a","article-title":"Melanoma drug wins US approval","volume":"471","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"R39-20230926","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejca.2011.09.018","article-title":"The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: summary of the scientific assessment of the Committee for Medicinal Products for Human Use","volume":"48","author":"Hanaizi","year":"2012","journal-title":"Eur J Cancer"},{"key":"R40-20230926","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R41-20230926","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"R42-20230926","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R43-20230926","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R44-20230926","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/EJE-13-0434","article-title":"Endocrine side-effects of anticancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses","volume":"169","author":"Torino","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"R45-20230926","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"R46-20230926","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jnci\/djr373","article-title":"Thyroid dysfunction from antineoplastic agents","volume":"103","author":"Hamnvik","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"R47-20230926","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"R48-20230926","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I\/II study","volume":"12","author":"Maker","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"R49-20230926","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4158\/EP11273.OR","article-title":"Association of ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series","volume":"18","author":"Min","year":"2012","journal-title":"Endocr Pract"},{"key":"R50-20230926","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"R51-20230926","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1078-0432.CCR-09-2033","article-title":"Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma","volume":"16","author":"Kirkwood","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R52-20230926","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1634\/theoncologist.2011-0404","article-title":"Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease","volume":"17","author":"Torino","year":"2012","journal-title":"Oncologist"},{"key":"R53-20230926","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"key":"R54-20230926","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0022-3476(04)00233-1","article-title":"Suppression of adrenal function in children with acute lymphoblastic leukemia following induction therapy with corticosteroid and other cytotoxic agents","volume":"144","author":"Mahachoklertwattana","year":"2004","journal-title":"J Pediatr"},{"key":"R55-20230926","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jpeds.2005.06.006","article-title":"Clinical impact of corticosteroid-induced adrenal suppression during treatment for acute lymphoblastic leukemia in children: a prospective observational study using the low-dose adrenocorticotropin test","volume":"147","author":"Rix","year":"2005","journal-title":"J Pediatr"},{"key":"R56-20230926","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1210\/jc.2006-2744","article-title":"Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study","volume":"92","author":"Greenfield","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R57-20230926","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/cen.12869","article-title":"Evaluation of adipocytokines and traditional cardiometabolic risk factors in young male cancer survivors: an age-matched control study","volume":"84","author":"Greenfield","year":"2016","journal-title":"Clin Endo"},{"key":"R58-20230926","first-page":"169","article-title":"Testosterone replacement in male cancer survivors improves body composition","volume":"38","author":"Walsh","year":"2017","journal-title":"Endocrine Reviews"},{"key":"R59-20230926","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"R60-20230926","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome \u2013 a new world-wide definition. A consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet Med"},{"key":"R61-20230926","doi-asserted-by":"crossref","first-page":"2048004016633371","DOI":"10.1177\/2048004016633371","article-title":"A clinical perspective of obesity, metabolic syndrome and cardiovascular disease","volume":"5","author":"Han","year":"2016","journal-title":"JRSM Cardiovasc Dis"},{"key":"R62-20230926","first-page":"3051","article-title":"Long-term survivors of childhood cancer have an increased risk of manifesting the metabolic syndrome","volume":"81","author":"Talvensaari","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"R63-20230926","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","article-title":"The metabolic syndrome","volume":"365","author":"Eckel","year":"2005","journal-title":"Lancet"},{"key":"R64-20230926","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s12265-012-9358-7","article-title":"Vascular injury in cancer survivors","volume":"5","author":"Mulrooney","year":"2012","journal-title":"J Cardiovasc Transl Res"},{"key":"R65-20230926","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1210\/jc.2006-2178","article-title":"Abdominal obesity, liver fat, and muscle composition in survivors of childhood acute lymphoblastic leukemia","volume":"92","author":"Janiszewski","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R66-20230926","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/pbc.25601","article-title":"Reduced insulin sensitivity in childhood survivors of haematopoietic stem cell transplantation is associated with lipodystropic and sarcopenic phenotypes","volume":"62","author":"Wei","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"R67-20230926","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.ATV.0000099786.99623.EF","article-title":"Adiponectin and metabolic syndrome","volume":"24","author":"Matsuzawa","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R68-20230926","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.bbmt.2016.05.007","article-title":"Metabolic Syndrome and cardiovascular disease after hematopoietic cell transplantation: screening and preventive practice recommendations from the CIBMTR and EBMT","volume":"22","author":"DeFilipp","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R70-20230926","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1542\/peds.2007-0575","article-title":"Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group","volume":"121","author":"Shankar","year":"2008","journal-title":"Pediatrics"},{"issue":"(Suppl 5)","key":"R71-20230926","doi-asserted-by":"crossref","first-page":"v277","DOI":"10.1093\/annonc\/mdq200","article-title":"Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines","volume":"21","author":"Bovelli","year":"2010","journal-title":"Ann Oncol"},{"key":"R73-20230926","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"key":"R74-20230926","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10552-012-0116-6","article-title":"Contribution of diet and physical activity to metabolic parameters among survivors of childhood leukemia","volume":"24","author":"Tonorezos","year":"2013","journal-title":"Cancer Causes Control"},{"key":"R75-20230926","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/pbc.25276","article-title":"Physical activity and cardiovascular risk factors in childhood cancer survivors","volume":"62","author":"Slater","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R76-20230926","doi-asserted-by":"crossref","first-page":"e763","DOI":"10.3399\/bjgp11X606771","article-title":"Cancer survivorship: the impact on primary care","volume":"61","author":"Watson","year":"2011","journal-title":"Br J Gen Pract"},{"key":"R77-20230926","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S1470-2045(15)00205-3","article-title":"The expanding role of primary care in cancer control","volume":"16","author":"Rubin","year":"2015","journal-title":"Lancet Oncol"},{"key":"R78-20230926","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/sj.bjc.6605160","article-title":"Follow-up care for cancer survivors: the views of clinicians","volume":"101","author":"Greenfield","year":"2009","journal-title":"Br J Cancer"}],"container-title":["Current Opinion in Supportive &amp; Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/01263393-201709000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:17:16Z","timestamp":1750378636000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01263393-201709000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":76,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/spc.0000000000000289","relation":{},"ISSN":["1751-4258","1751-4266"],"issn-type":[{"value":"1751-4258","type":"print"},{"value":"1751-4266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]}}}